The bivalent mRNA boosters from Pfizer-BioNTech and Moderna were 48% effective against symptomatic infection from the predominant omicron subvariant (XBB/XBB.1.5) in persons aged 18-49 years according to early data published by the CDC nbcnews.com Submitted by shiruken t3_10lcgah on January 25, 2023 at 10:58 PM in science 75 comments 337
nirad t1_j61egkp wrote on January 27, 2023 at 12:47 AM Perhaps this is why XBB 1.5 hasn't resulted in a massive spike in cases and hospitalization, despite it's high R0. Permalink 2
Viewing a single comment thread. View all comments